SOHM, Inc (SHMN) Fair Value & Analysis
Healthcare · US · Market cap $3.2M
SOHM, Inc
SHMN · US
Fair value as of: Jun 25, 2026
From 7 valuation models · updated 8 days ago
Fair value updated Jun 25, 2026 — revised from $0.0100 to $0.0013 (−87.0%) since Jun 24, 2026. Share price −16.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0007 – $0.0019 · the $0.0010 price screens below the $0.0013 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SOHM, Inc (SHMN) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0013 — implying the stock looks roughly 30.0% undervalued today. We read business quality at 36/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, SOHM, Inc generated revenue of $1.3M at a net margin of -87.3%. Revenue declined 45.2% year over year. Net debt stands at $2.6M. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
SOHM, Inc. develops, manufactures, markets, and distributes generic and private label pharmaceutical products in the United States. The company offers analgesics, antibiotics, anti-cold, and anti-inflammatory drugs, as well as over-the-counter, cosmeceuticals, and nutraceutical products. It also exports its products. The company has collaboration agreement with Coastar Therapeutics to advance in the field of genome editing using red blood cell membrane derived carriers and genome editing technology. SOHM, Inc. was founded in 2005 and is based in Corona, California.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SOHM, Inc reported revenue of $1.2M in FY2025 versus $325K in FY2021, a compound +38.0%/yr. Reported net income was −$506K in FY2025.
Is SHMN fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SOHM, Inc (SHMN) undervalued?
What is the fair value of SHMN?
What is the quality score of SHMN?
What is the revenue of SOHM, Inc (SHMN)?
What is the net profit margin of SHMN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.